Forty-year journey of angiogenesis translational research.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 22190240.
- Also identified by DOI 10.1126/scitranslmed.3003149 and PMC identifier 8265598.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Forty years ago, Judah Folkman predicted that tumor growth is dependent on angiogenesis and that inhibiting this process might be a new strategy for cancer therapy. This hypothesis formed the foundation of a new field of research that represents an excellent example of how a groundbreaking scientific discovery can be translated to yield benefits for patients. Today, antiangiogenic drugs are used to treat human cancers and retinal vascular diseases. Here, we guide readers through 40 years of angiogenesis research and discuss challenges of antiangiogenic therapy.
Medical subject headings
- Neovascularization, Pathologic